Raimondi et al., 2020 - Google Patents
Non-coding RNAs in multiple myeloma bone disease pathophysiologyRaimondi et al., 2020
View HTML- Document ID
- 14118153183624177727
- Author
- Raimondi L
- De Luca A
- Giavaresi G
- Raimondo S
- Gallo A
- Taiana E
- Alessandro R
- Rossi M
- Neri A
- Viglietto G
- Amodio N
- Publication year
- Publication venue
- Non-coding RNA
External Links
Snippet
Bone remodeling is uncoupled in the multiple myeloma (MM) bone marrow niche, resulting in enhanced osteoclastogenesis responsible of MM-related bone disease (MMBD). Several studies have disclosed the mechanisms underlying increased osteoclast formation and …
- 206010035226 Plasma cell myeloma 0 title abstract description 225
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
Similar Documents
Publication | Publication Date | Title |
---|---|---|
He et al. | The roles and mechanisms of lncRNAs in liver fibrosis | |
Razmara et al. | Non-coding RNAs in cartilage development: an updated review | |
Li et al. | Characterization of hsa_circ_0004277 as a new biomarker for acute myeloid leukemia via circular RNA profile and bioinformatics analysis | |
Rinnerthaler et al. | miR-16-5p is a stably-expressed housekeeping microRNA in breast cancer tissues from primary tumors and from metastatic sites | |
Raimondo et al. | Extracellular vesicle microRNAs contribute to the osteogenic inhibition of mesenchymal stem cells in multiple myeloma | |
Sepramaniam et al. | Circulating microRNAs as biomarkers of acute stroke | |
Liao et al. | Expression profiling of exosomal miRNAs derived from human esophageal cancer cells by Solexa high-throughput sequencing | |
Kutsche et al. | Combined experimental and system-level analyses reveal the complex regulatory network of miR-124 during human neurogenesis | |
Aurilia et al. | The involvement of long non-coding RNAs in bone | |
Liu et al. | MicroRNA-944 affects cell growth by targeting EPHA7 in non-small cell lung cancer | |
Raimondi et al. | Non-coding RNAs in multiple myeloma bone disease pathophysiology | |
Kim et al. | STAT3 inhibitor ODZ10117 suppresses glioblastoma malignancy and prolongs survival in a glioblastoma xenograft model | |
Watanabe et al. | A human skin model recapitulates systemic sclerosis dermal fibrosis and identifies COL22A1 as a TGFβ early response gene that mediates fibroblast to myofibroblast transition | |
Chen et al. | Advances of exosomal miRNAs in breast cancer progression and diagnosis | |
Yang et al. | Identification of recurrence related microRNAs in hepatocellular carcinoma after surgical resection | |
Federico et al. | Circulating microRNAs and their role in multiple myeloma | |
Coppola et al. | S-Adenosylmethionine inhibits cell growth and migration of triple negative breast cancer cells through upregulating MiRNA-34c and MiRNA-449a | |
Indio et al. | Gene expression landscape of SDH-deficient gastrointestinal stromal tumors | |
Freire et al. | Decreased mir-497-5p suppresses il-6 induced atrophy in muscle cells | |
Nikolova et al. | Coupling miR/isomiR and mRNA expression signatures unveils new molecular layers of endometrial receptivity | |
Laudadio et al. | ZNF281 promotes colon fibroblast activation in tgfβ1-induced gut fibrosis | |
Ronchetti et al. | In silico characterization of miRNA and long non-coding RNA interplay in multiple myeloma | |
Dreher et al. | TGF-β Induction of miR-143/145 is associated to exercise response by influencing differentiation and insulin signaling molecules in human skeletal muscle | |
Kuscu et al. | Integrative analyses of circulating small RNAs and kidney graft transcriptome in transplant glomerulopathy | |
Araldi et al. | LIMD2 regulates key steps of metastasis cascade in papillary thyroid cancer cells via MAPK crosstalk |